Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
X4 Pharmaceuticals reports positive Phase 2 results for mavorixafor in chronic neutropenia, with Phase 3 4WARD trial on track for mid-2025 enrollment. U.S. launch of XOLREMDI® (mavorixafor) for WHIM syndrome underway, with EMA MAA submission expected by early 2025.
ME Therapeutics Holdings Inc. Provides Research and Development Update and Corporate Update
ME Therapeutics updates on progress with anti-G-CSF antibody candidate h1B11-12, aiming for a 2025 GMP production and clinical trial. The company plans to move into new lab and office space, enhancing research capabilities and exploring drug discovery opportunities. Management is also pursuing in-licensing and partnership opportunities to strengthen the drug pipeline.
Sardesai Discusses ADC Selection Based on HR and HER2 Status in mBC
Experts discuss the use of sacituzumab govitecan and trastuzumab deruxtecan in breast cancer treatment, focusing on safety profiles, supportive care, and therapeutic sequencing. They highlight the importance of G-CSF use, the modest overall survival improvement with sacituzumab, and the better tolerability of trastuzumab deruxtecan. The discussion also covers the management of treatment-related toxicities, particularly neutropenia and diarrhea, and the need for early intervention with steroids to mitigate adverse effects.
Related Clinical Trials:
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in ...
Article references discuss various therapies, transplantation methods, and maintenance strategies for myeloma, including triplet therapy, lenalidomide-bortezomib-dexamethasone with transplantation, and plerixafor-G-CSF for stem cell mobilization.
Isa-KRd Induction Therapy Elicits Responses, MRD Negativity in Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients
The phase 3 IFM2020-02 MIDAS study interim analysis showed that 6 cycles of isatuximab-irfc, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) induction therapy achieved a 95% overall response rate (ORR) in newly diagnosed multiple myeloma patients eligible for transplant, with 63% MRD negativity at 10-5 and 47% at 10-6. The study also demonstrated manageable safety and successful stem cell collection. The ongoing MIDAS trial is evaluating an MRD-adapted consolidation and maintenance strategy following Isa-KRd induction.
Related Clinical Trials:
Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
Generics and biosimilars saved $445 billion in 2023, totaling $3.1 trillion over 10 years, with 90% of US prescriptions and 13% of drug spending. Biosimilars alone saved $12.4 billion in 2023, totaling $36 billion since 2015, benefiting patients with conditions like heart disease, mental health, and cancer. States averaged over $8 billion in savings, with California leading at nearly $38 billion.
FDA Grants Orphan Drug Designation to Tebapivat for MDS
The FDA granted orphan drug designation to tebapivat (AG-946) for treating myelodysplastic syndromes (MDS). Tebapivat is being studied in a phase 2 trial for anemia in lower-risk MDS, with phase 2a data showing 4 out of 10 low transfusion burden patients achieving transfusion independence. The phase 2b study will continue to evaluate tebapivat in patients with lower-risk MDS, focusing on transfusion independence as the primary endpoint.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath